Capricor Therapeutics CFO Sells Shares

Anthony Bergmann, the Chief Financial Officer of Capricor Therapeutics, Inc. (NasdaqGS: CAPR), sold 400 shares of the company's stock on June 24, 2026. The shares were sold at an average price of $30.00, totaling $12,000. This transaction was not part of a pre-arranged trading plan.

Insider Buying and Selling at Capricor Therapeutics, Inc.

On the same day, Karen Krasney, EVP and General Counsel of Capricor, also sold 400 shares at the same price of $30.00. These transactions reflect active insider trading activity at the company.

Other Institutional Activity in Capricor Therapeutics

Several institutional investors have also been active in Capricor Therapeutics. Suvretta Capital Management, LLC increased its holdings by 2,032,990 shares, bringing its total to 3,818,600 shares valued at approximately $116.1 million. BlackRock, Inc. added 570,837 shares, ending with 3,421,815 shares worth about $104 million. Tang Capital Management LLC doubled its position, adding 1,699,900 shares for a total of 3,399,900 shares valued at around $103.4 million. State Street Corp significantly boosted its stake by 1,352,380 shares, totaling 2,181,901 shares valued at $66.3 million. Vanguard Capital Management LLC opened a new position with 2,027,732 shares valued at approximately $61.6 million.

Capricor Therapeutics, Inc. Stock Up 207.7%

Shares of Capricor Therapeutics traded near $29.60 on Thursday. The company has a market capitalization of about $1.7 billion. While it isn't currently profitable, it has a forward P/E ratio of -38.42, reflecting its status as a clinical-stage biotechnology firm. The stock has seen a 52-week low of $4.30 and a high of $40.37. It maintains a strong current ratio of 8.42, indicating robust liquidity.

Analysts Set New Price Targets

Several analysts have reiterated their positive outlook on Capricor Therapeutics. On March 13, 2026, B. Riley Securities maintained a 'buy' rating with a price target of $63. Piper Sandler also reiterated a 'buy' rating, setting a target of $58. HC Wainwright & Co. reaffirmed its 'buy' rating with a target of $60 earlier in March.

About Capricor Therapeutics

Capricor Therapeutics, Inc. is a biotechnology company based in San Diego, California. It focuses on developing cell and exosome-based therapies for diseases with unmet needs, like Duchenne muscular dystrophy. Its leading candidate, Deramiocel, is in phase 3 trials, while it also explores exosome-based vaccines and therapeutics. The company was founded in 2005 and is led by CEO Dr. Linda Marbán.

Bottom Line

Insider transactions, like those by Anthony Bergmann, can offer insights into company sentiment, though they don't always predict future stock performance. Capricor Therapeutics is a clinical-stage biotech firm with a strong pipeline and substantial institutional interest. Analysts continue to favor the stock, underscoring the company's potential in the healthcare sector.